Background The Vaccine Safety Datalink (VSD) detected a statistical signal for ischemic events (ischemic stroke or transient ischemic attack) following bivalent mRNA COVID-19 vaccination through prospective surveillance during 2022–2023. Although multiple studies from other surveillance systems and countries reported no increased risk, important methodological limitations remained. This U.S. study addressed those limitations by evaluating the ischemic stroke risk following bivalent mRNA COVID-19 vaccination, influenza vaccination, and their same-day coadministration using an event-dependent self-controlled case series (SCCS) design. Methods Study outcomes included first-ever ischemic stroke (primary outcome), first-in-1-year ischemic stroke (secondary outcome), and ischemic events (exploratory outcomes), identified using ICD-10-CM codes in inpatient and emergency department settings during September 1, 2022–March 31, 2023, among individuals aged ≥12 years across eight VSD sites. Analyses were conducted separately for Pfizer-BioNTech and Moderna bivalent vaccines, with relative incidences (RI) and 95% confidence intervals (CI) estimated for 1–21-day and 1–42-day risk intervals, using person-time outside these intervals as the control period. Subgroup analyses were performed by age group (12–64, ≥65 years) and history of documented SARS-CoV-2 infection. Results A total of 6510 first-ever ischemic strokes were identified among more than 6.8 million participants. Among recipients of Pfizer-BioNTech bivalent COVID-19 and influenza vaccines, no statistically significant increased risk of first-ever ischemic stroke was observed following bivalent COVID-19 vaccination (RI = 0.94; 95% CI: 0.63–1.41), influenza vaccination (RI = 0.95; 95% CI: 0.82–1.10), or same-day coadministration (RI = 1.15; 95% CI: 0.88–1.49) within 1–21-day risk intervals; findings were similar for 1–42-day intervals. Comparable null results were observed for Moderna vaccine and across all subgroups, secondary, and exploratory outcomes. Conclusion No increased risk of ischemic stroke was found following bivalent mRNA COVID-19 vaccination, influenza vaccination, or their coadministration in this multi-site SCCS study. These findings are consistent with previous studies and underscore the importance of continued vaccine safety monitoring.
Severe hypoglycemia is a feared complication of diabetes treatment. While psychoeducational programs reduce severe hypoglycemia in type 1 diabetes, their effectiveness is unclear in type 2 diabetes (T2D). The Preventing Severe Hypoglycemia in Adults with Type 2 Diabetes (PHT2) randomized trial compared (a) proactive nurse care management (PC) and (b) PC augmented with my hypo compass for adults with T2D, a psychoeducational intervention (PC+). Adults with T2D on insulin or sulfonylurea and with a severe event in the prior 12 months or impaired awareness of hypoglycemia. Primary outcome was self-reported severe hypoglycemia over 12 months, assessed at 14 months. Ninety-two percent (n = 230) of 259 participants (67.2 ± 10.6 years; 61
BACKGROUND/AIMS: Evaluating heterogeneity of treatment effects (HTE) across subgroups is common in both randomized trials and observational studies. Although several statistical challenges of HTE analyses including low statistical power and multiple comparisons are widely acknowledged, issues specific to clustered data, including cluster randomized trials (CRTs), have received less attention. For testing interactions in linear mixed-effects models (LMM), Barr et al. (2013) suggested that: random slopes for interaction terms should be studied. In this paper, we explore the impact of model misspecification, including generalized LMM (GLMM) with or without random slopes, and provide recommendations for conducting inference for HTE across subgroups in CRTs. METHODS: We conducted a simulation study to evaluate the performance of common analytic approaches for testing the presence of HTE for continuous, binary, and count outcomes: generalized linear mixed models (GLMM) and generalized estimating equations (GEE) including interaction terms between treatment and subgroup. Several simulation scenarios covered broad range of scenarios in CRTs, for example, small to a large number of clusters, small to moderate cluster-specific random slopes for subgroup. The performance metric was the empirical type I error rate compared to a nominal level. We applied the analytical methods to a real-world CRT using the count outcome utilization of healthcare from the motivating Primary Care Opioid Use Disorder treatment (PROUD) trial. RESULTS: We found that standard GLMM analyses that assume a common correlation of participants within clusters can lead to severely elevated type 1 error rates of up to 47.2% compared to the 5% nominal level if the within-cluster correlation varies across subgroups. A maximal GLMM, which allows subgroup-specific within-cluster correlations, achieved the nominal type 1 error rate, as did GEE (though rates were slightly elevated even with as many as 50 clusters). Applying the methods to the real-world CRT, we found a large impact of the model specification on inference. CONCLUSIONS: We recommend that HTE analyses using the maximal GLMM account for within-subgroup correlation to avoid anti-conservative inference. For Wald t-testing of HTE in small sample clusters, appropriate small sample correction methods should be considered based on the outcome data type.
In a typical two-phase design, a random sample is drawn from the target population in phase 1, during which only a subset of variables is collected. In phase 2, a subsample of the phase-1 cohort is selected, and additional variables are measured. This setting induces a coarsened data structure on the data from the second phase. We assume coarsening at random, that is, the phase-2 sampling mechanism depends only on variables fully observed. We review existing estimators, including the generalized raking estimator and the inverse probability of censoring weighted targeted maximum likelihood estimation (IPCW-TMLE) along with its extensions that also target the phase-2 sampling mechanism to improve efficiency. We further introduce a new class of estimators constructed within the TMLE framework that are asymptotically equivalent.